Enclomiphene is the trans isomer of clomiphene, a selective estrogen receptor modulator (SERM). In men it has been studied as a way to raise the body's own LH, FSH and testosterone instead of replacing testosterone.
Also known as: Androxal (proposed name), trans-clomiphene.
There is no FDA-approved enclomiphene product. The new drug application Repros Therapeutics filed (NDA 207959, proposed name Androxal) was for 12.5 mg and 25 mg oral capsules.
Enclomiphene is not FDA approved. In December 2015 Repros announced a complete response from the FDA on its application for secondary hypogonadism. FDA has since said the phase 3 design was no longer adequate to show clinical benefit, and also raised concerns about entry criteria, titration and bioanalytical methods. A separate application in Europe was recommended for refusal by the EMA in January 2018.
For compounding, FDA's Pharmacy Compounding Advisory Committee voted 4 to 8 on June 8, 2022 against adding enclomiphene citrate to the 503A bulk substances list. On FDA's list updated May 14, 2026, it sits in Category 1 ("under evaluation"), with no final decision.
In a phase 2 trial, enclomiphene raised testosterone while sperm counts were largely preserved (Wiehle, Fertil Steril 2014). The AUA 2018 guideline says clinicians may use SERMs, hCG or aromatase inhibitors in men with testosterone deficiency who want to maintain fertility (a conditional recommendation), and notes that only hCG is FDA approved for use in males. These are trial protocols, not personalized advice; confirm any dosing with your prescriber. See hCG vs enclomiphene and Estradiol (E2) on TRT.
Published half-life estimates for enclomiphene vary: FDA's 2022 compounding committee briefing cites about 10 hours, while other sources differ, so we do not list a single number. That briefing and a phase 2 study (Wiehle 2013) report peak levels 2 to 3 hours after a dose, and absorption increases with food.
Numbers shown are the values Dose Track uses, listed only where they agree with the source above. Half-life varies from person to person and with injection site.